Tue.Feb 13, 2024

article thumbnail

Biogen CEO plots long-term turnaround after analysts brand company's recent results as 'weak'

Fierce Pharma

While Biogen’s financials are in rough shape now, the company’s CEO, Chris Viebacher, sees reason to be optimistic about the future. | With four new drug launches rolling and the majority of the company’s losses of exclusivity in the rearview, Biogen figures it could chart continued revenue growth over the next 10 years, CEO Chris Viehbacher said Tuesday.

294
294
article thumbnail

AI Biotech Exscientia Fires CEO Hopkins for Relationships With Two Employees

MedCity News

Exscientia’s termination of CEO Andrew Hopkins is for cause and effective immediately. Grounds for termination include misconduct or behavior that brings Hopkins or the company into disrepute, according to his employment agreement.

Biopharma 123
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

With FDA nod for Onivyde combo, Ipsen ends 10-year drought in newly diagnosed pancreatic cancer

Fierce Pharma

It’s the approval Ipsen has been waiting for since buying up Onivyde in 2017. | It’s the approval Ipsen has been waiting for since buying up Onivyde in 2017. The FDA has approved Onivyde as part of a combination dubbed Nalirifox to treat patients with newly diagnosed metastatic pancreatic cancer.

FDA 284
article thumbnail

Vertex secures European approval for CRISPR cell therapy

European Pharmaceutical Review

The first CRISPR/Cas9 gene-edited therapy has been granted a marketing authorisation by the European Commission (EC). Vertex Pharmaceuticals’ CASGEVY ( exagamglogene autotemcel [exa-cel]) is conditionally approved individuals 12 years and over with severe sickle cell disease characterised by recurrent vaso-occlusive crises or transfusion-dependent beta thalassemia.

article thumbnail

AI Strategies for Sales Managers: How to Cut Down on Tedious Admin Work

What if you could help your sellers stop wasting 72% of their day on non-selling activities and focus on bringing in revenue? Incorporating AI in your enablement workflows can help you cut down on busy work, get projects done faster, and let your team (and you!) focus on making a bigger impact. We put together this guide to show you how to use AI to cut time and costs for projects, including collateral creation, development of training videos, and automating tedious processes.

article thumbnail

Lawmakers urge White House officials to enforce sanctions on China's WuXi AppTec, WuXi Biologics: Reuters

Fierce Pharma

After introducing legislation targeting certain Chinese biopharma companies, a group of bipartisan lawmakers are taking their concerns to the White House—and upping the stakes. | After proposing a bill to revoke funding from certain Chinese biopharmas, a group of bipartisan legislators penned a letter to certain White House officials pressing for sanctions on the two companies based on alleged links to China's Communist Party and its military.

Biopharma 280
article thumbnail

Biogen’s Skyclarys is first EU drug for Friedreich’s ataxia

pharmaphorum

Biogen’s Skyclarys is the first approved medicine for the inherited neurological disease Friedreich’s ataxia (FA) in the EU, after getting a green light from the European Commission.

Medicine 112

More Trending

article thumbnail

Bridging the Data Divide: Investing in People and Tech to Improve Health Equity

MedCity News

Proper data collection, analysis, and utilization has the potential to address long-standing health disparities and propel our healthcare system forward to serve all communities.

article thumbnail

With UK appeals court win, GSK avoids paying larger share of Zejula sales to AstraZeneca

Fierce Pharma

It appears GSK won’t have to fork over extra Zejula royalties to AstraZeneca after all, thanks to an appeals court victory in the companies’ long-running U.K. legal dispute. | GSK was previously ordered to pay rival PARP inhibitor maker AstraZeneca a larger share of total sales on its cancer med Zejula. But an appeals court has overturned the decision.

Sales 144
article thumbnail

Employers Have a Pain Problem

MedCity News

There is some acknowledgment by employers of their pain problem, but this awareness is not universal. This demonstrates a clear need for solutions that tackle not only health care costs, but absenteeism, the impact to presenteeism, and overall productivity.

109
109
article thumbnail

PhRMA lawsuit challenging IRA price negotiations dismissed on jurisdictional technicality

Fierce Pharma

A federal judge has tossed a lawsuit by industry lobbying group PhRMA which challenged the legality of Medicare price negotiations.

183
183
article thumbnail

From Diagnosis to Delivery: How AI is Revolutionizing the Patient Experience

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

article thumbnail

USP recommends revisions to proposed RMM chapters

European Pharmaceutical Review

In January, United States Pharmacopeia (USP) published revisions to previous drafts of chapters about using rapid microbiological methods (RMM), with a specific focus on short-life products. <72> Respiration-Based Microbiological Methods for the Detection of Contamination in Short-Life Products The changes for the proposed chapter the detection of contaminants in short-life products.

Media 98
article thumbnail

Biomarkers ‘may predict dementia 15 years before diagnosis’

pharmaphorum

Researchers have used proteomics data from the UK Biobank to identify protein biomarkers in blood that could give warning of dementia years before diagnosis

107
107
article thumbnail

UK Agency targets blood thinners in personalised medicine pursuit

Pharmaceutical Technology

The MHRA kicks off phase two of the Yellow Card biobank to explore the genetic link to side effects of direct oral anticoagulants.

article thumbnail

Headlight Secures $18M in Funding To Improve Access to Mental Health Support

MedCity News

Headlight’s funding round was led by Matrix and EPIC Ventures. The company also hired new leadership, including CEO Geoff Swindle, who was formerly chief business officer at PillPack and Amazon Pharmacy.

98
article thumbnail

How to Prove Marketing Value: Demonstrate Content ROI and Contribution to Sales

Every marketer knows how important it is to prove their efforts drive sales opportunities, but that’s easier said than done. When problems like sales and marketing misalignment, lack of data, and wasted efforts persist, marketers can’t measure, prove, or increase their impact on revenue at a time when demonstrating marketing value is critical. Using analyst and expert data, this guide to marketing impact and content attribution explains: How B2B buyers use content The most common types of conten

article thumbnail

White House wins in first Medicare negotiation legal ruling

pharmaphorum

Texas judge has thrown out the first lawsuit brought by PhRMA claiming Medicare negotiation of drug pricing is unconstitutional

105
105
article thumbnail

CRISPR gene therapy Casgevy secures approval in Europe

Pharmaceutical Technology

The regulatory greenlight makes it the only gene therapy available in Europe for sickle cell disease and TDT.

105
105
article thumbnail

Roche, PathAI team up on AI companion diagnostics

pharmaphorum

Roche has turned to artificial intelligence specialist PathAI to accelerate its development of digital pathology technologies that can be used to match patients with drug treatments and support new drug development. The alliance is with Roche Tissue Diagnostics (RTD), a unit of the Swiss pharma group that is concerned with the development of tissue-based tools to improve the diagnosis of cancer and grew out of Roche’s acquisition of Venta Medical Systems in 2008.

Pharma 69
article thumbnail

Surviving Cancer And Making An Impact To Cancer Patients’ Lives With Rob Ciaramitaro

Evolve Your Success

The biggest challenges in our lives should not stop us in our tracks, but rather open up new possibilities for a more meaningful life. Cancer survivor Rob Ciaramirato fully embraced this mindset, unleashing a more purposeful version of himself after going through one of his biggest tests. In this special episode for World Cancer Day, he joins Samuel Adeyinka in looking back how being diagnosed and surviving cancer made him realize the purposeful things he can do through medical sales.

article thumbnail

Optimizing Clinical Supply Strategy: Navigating Challenges & Finding Your Ideal Model

article thumbnail

Network With More Than 100 Healthcare VC firms at MedCity INVEST 2024!

MedCity News

The conference is the premier boutique healthcare investment event in the U.S.

article thumbnail

Aligning Resources with Needs: Enhancing Hospital Demand Forecasting for Better Care

Clarify Health

In healthcare, the ability to predict future demand with precision is not just a competitive advantage. For many hospitals and healthcare systems, it’s a necessity for survival. Optimizing resources to meet the moment calls for strategic planning powered by healthcare data analytics and effective demand forecasting. Demand forecasting in the context of hospital systems is critical for aligning resources like staff, equipment, and beds with future patient care needs.

article thumbnail

Roche Pulls Out of Agreement With Repare Therapeutics to Develop Novel Cancer Therapy

Pharmaceutical Commerce

Roche and Repare came to terms on a deal in June 2022 to develop and commercialize camonsertib, which included a $125 million upfront payment and could have reached up to $1.2 billion based on clinical, regulatory, commercial, and sales milestones.

Sales 52
article thumbnail

Roche Ends Agreement With Repare Therapeutics to Develop ATR Inhibitor Camonsertib

PharmExec

Roche halts agreement with Repare Therapeutics to develop and commercialize camonsertib just weeks after triggering a $40 million milestone payment when the first patient was dosed with the novel cancer drug.

article thumbnail

Increase Revenue With Better, Faster Sales Onboarding

Quotas need to be hit. Revenue goals need to be met. This reality makes shortening sales onboarding time a top priority. Organizations with a standard onboarding process boost employee retention by 58% and increase productivity by 50%. Unfortunately, many companies struggle with inefficient processes that lead to high turnover and missed revenue opportunities.

article thumbnail

FDA Fast Tracks Novel Treatment for Metastatic Small Cell Neuroendocrine Prostate Cancer

Pharmaceutical Commerce

BXCL701 combined with Keytruda (pembrolizumab) is being evaluated for patients with metastatic castration-resistant prostate cancer with small cell neuroendocrine and adenocarcinoma phenotypes.

FDA 52
article thumbnail

Building Resiliency: Essential Leadership Principles for 2024

PharmExec

Embracing business imperatives such as operational efficiency and a focus on a patient-centric approach can help pharma leaders provide a stable foundation amid lingering uncertainty.

Pharma 52
article thumbnail

How to Land a Job in Pharmaceutical Sales for 2024 and Beyond

Contrarian Sales Techniques

So, you've got your sights set on the pharmaceutical sales world for 2024, huh? It might be your smartest choice ever but don’t throw in the party yet. No doubt that this is a sector where you can really make a mark, not just in terms of a solid career but also in making a difference in people's lives. (Why choose pharma sales job? Here’s my thought ).

article thumbnail

Launch Readiness 2024: A fresh look at key trends affecting pharma product launches

Tribeca Knowledge

I n our latest report, Launch Readiness 2024 , we look at the prospects and obstacles facing new medicines in markets still recovering from the COVID-19 pandemic. We consider the current state of companies’ R&D pipelines, where there are opportunities for launch excellence, and how launch planners can best negotiate the many and varied market-access challenges further complicated by the legacy effects of COVID-19.

article thumbnail

European Clinical Supply Planning: Balancing Cost, Flexibility and Time

article thumbnail

How AI Can Help Solve Drug Shortage Issues

Pharmaceutical Commerce

In this video interview with Associate Editor Miranda Schmalfuhs, Dr. Jo Varshney, CEO & Founder of VeriSIMLife, discusses how artificial intelligence and machine learning can assist in the drug shortage problem.

52
article thumbnail

How Clarivate works towards SDG 9: Build resilient infrastructure, promote inclusive and sustainable industrialization and foster innovation

Clarivate

At Clarivate we put sustainability at the heart of our business goals. Environment, social and governance issues are at the core of our global culture, serving as guiding principles for every decision we make. Our sustainability report is full of real-life examples of how we help our customers, colleagues and communities, with transparent, data-driven results and real insights on where we need to focus moving forward.

article thumbnail

Developing a Robust Serialization Program

Pharmaceutical Commerce

Various considerations can help pharmaceutical manufacturers and suppliers provide a robust serialization solution based on the FDA's Drug Supply Chain Security Act.

article thumbnail

Why patient centricity is the answer to the clinical trial enrolment gap 

Pharmaceutical Technology

Research indicates that designing clinical trials with the patient in mind reduces recruitment times and enhances trial performance.

article thumbnail

Using Generative AI in Sales: Pros, Cons, and Considerations According to Sellers

Are your sellers unsure about using AI in their day-to-day workflows? Or are they eager to try but uncertain where to start? They might be asking: Which tasks are best suited for AI? How will using AI affect my relationship with my customers? With so many tools available, which ones are the most useful to me? To help answer these and other common questions about using AI during the sales cycle, we surveyed B2B sellers who were early adopters to get their insight and advice about how to use gen A